MED17

Across TCGA pan-cancer cohorts, MED17 RNA is linked to patient survival in 28 of 34 cancer types, making it the most broadly survival-associated MED17 data layer compared with 8 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MED17 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MED17 expression acts as an unfavorable survival marker, although some lineages such as KIRC and UCS show a favorable association.

LIHC, KIRC, and UCS are the cancer types where MED17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.466	0.613	<.001	62	view →
KIRC	OS	Tertile	All	0.724	0.508	<.001	59	view →
UCS	DFS	Median	IV	0.952	0.367	.001	44	view →
BRCA	OS	Tertile	II,III,IV	0.890	0.954	<.001	38	view →
ACC	DFS	Median	All	0.304	0.592	.003	37	view →
THCA	DFS	Quartile	All	0.971	0.652	.005	31	view →
READ	OS	Quartile	All	0.974	0.334	.001	28	view →
LUSC	DFS	Quartile	III,IV	0.210	0.950	.001	22	view →
PAAD	OS	Quartile	All	0.458	0.774	.002	21	view →
GBM	DFS	Median	All	0.397	0.186	.001	18	view →
DLBC	DFS	Quartile	II,III,IV	0.379	0.883	.029	16	view →
THYM	DFS	Quartile	All	1.000	0.823	.006	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 28 lineages.

MED17–LIHC (DFS)

Open the LIHC breakdown →